Inflammation News and Research

RSS

Newly published research examines association between CKD and CYP24

Cytochroma today announced the publication of new data from studies in a preclinical model indicating that chronic kidney disease is associated with markedly increased expression of the vitamin D catabolic enzyme, CYP24, which contributes to vitamin D insufficiency and resistance to vitamin D therapy. Parallel analysis of kidney biopsies obtained from CKD patients confirmed abnormal CYP24 expression in human disease as well.

16 Jun 2010

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Biogen Idec today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS).

15 Jun 2010

Asterand subsidiary BioSeek signs agreement with Amylin

Asterand plc, a leading provider of human tissue and human tissue-based research services to pharmaceutical and biotechnology companies engaged in drug discovery, today announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a one-year collaboration agreement with Amylin Pharmaceuticals, Inc.

14 Jun 2010

Research highlights importance of CT scanning in severe asthma patients

A new study led by University of Leicester researchers at Glenfield Hospital suggests that CT scans may be the way forward for monitoring progression of severe asthma as well as checking how it is responding to treatment.

14 Jun 2010

TWI launches new educational module to understand role of biofilms in chronic wound infections

The Wound Institute today announced the launch of a new educational module "Exploring Biofilms," an accredited, online course designed to help practicing wound care specialists better understand the role that biofilms play in chronic wound infections.

14 Jun 2010

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

A team of researchers at Childrens Hospital Los Angeles (CHLA), along with colleagues from the Keck School of Medicine of the University of Southern California and the Universite Auvergne, France, have discovered an important role for a small, naturally occurring protein called interleukin-10 (IL-10) in removing bacteria from the blood of infected mice and reversing damage to the brain.

11 Jun 2010

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, commented today on a recent study in The Journal of Medicine that both raw and cooked ginger reduce pain associated with muscle injury by about 24%, compared with placebo. The study was supported by the McCormick Science Institute.

10 Jun 2010

Allopurinol exhibits potential benefits for CKD patients

A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The research is the first to show that allopurinol treatment in patients with chronic kidney disease (CKD) decreases inflammation, slows the progression of kidney disease, and reduces patients' risk of experiencing a cardiovascular event or being hospitalized.

10 Jun 2010

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.

10 Jun 2010

Protagen, Bayer Schering Pharma close cooperation contract for biomarker discovery in Endometriosis

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, and Bayer Schering Pharma AG, a global leading specialty pharmaceuticals company, announced today the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.

10 Jun 2010

Abnormalities in the process of blood clot formation contribute to pathogenesis of AD: Research

New research suggests that abnormalities in the process of blood clot formation may contribute to the pathogenesis of Alzheimer's disease. The study, published by Cell Press in the June 10 issue of the journal Neuron, advances our understanding of the link between vascular pathology and AD and proposes a new therapeutic strategy aimed at slowing cognitive decline.

10 Jun 2010

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.

9 Jun 2010

Some commonly used drugs cause bone loss: New research

New research helps to explain why some commonly used drugs come with a serious downside: They up your odds of breaking a bone. The drugs in question, glucocorticoids (e.g. cortisone and prednisone) and the insulin sensitizer rosiglitazone work through entirely different mechanisms as therapies for inflammatory diseases and diabetes respectively, and two studies in the June issue of Cell Metabolism now show that they lead to bone loss in different ways too.

9 Jun 2010

NexGen Biomedical offers RNAi / PSR platform technology for sale

NexGen Biomedical, Inc. announced today that it is offering its RNAi / PSR platform technology for sale. "While technologies like siRNA are well suited for disease conditions involving expression of a single protein, the RNAi / PSR technology is better suited for conditions involving expression of a broad spectrum of proteins such as happens with cell hyperproliferation, inflammation, and viral infections.

8 Jun 2010

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Aerovance Inc. today announced top-line results from its Phase 2b clinical trial that show the inhaled dry powder formulation of Aerovant (pitrakinra inhalation powder) is effective in a pre-defined subset of patients with eosinophilic asthma.

8 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia, provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

7 Jun 2010

Inflammation News and Research

Newly published research examines association between CKD and CYP24

Biogen Idec initiates enrollment in Phase II BG-12 combination trial for relapsing-remitting multiple sclerosis

Asterand subsidiary BioSeek signs agreement with Amylin

Research highlights importance of CT scanning in severe asthma patients

TWI launches new educational module to understand role of biofilms in chronic wound infections

Protein IL-10 removes Escherichia coli K1 bacterium from blood and reverses brain damage

Raw and cooked gingers reduce pain associated with muscle injury by 24%: Reed's

Allopurinol exhibits potential benefits for CKD patients

Preclinical data of VB-201 to be presented at EULAR Annual European Congress of Rheumatology

Protagen, Bayer Schering Pharma close cooperation contract for biomarker discovery in Endometriosis

Abnormalities in the process of blood clot formation contribute to pathogenesis of AD: Research

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Some commonly used drugs cause bone loss: New research

NexGen Biomedical offers RNAi / PSR platform technology for sale

Aerovance reports top-line results from Aerovant Phase 2b clinical trial for eosinophilic asthma

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News